Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar;4(2):53-61.

Current management of inflammatory bowel disease and colorectal cancer

Current management of inflammatory bowel disease and colorectal cancer

Mark C Mattar et al. Gastrointest Cancer Res. 2011 Mar.

Abstract

INFLAMMATORY BOWEL DISEASES (IBDS) CAN BE DIVIDED INTO TWO MAJOR DISORDERS: ulcerative colitis and Crohn's disease. Although IBD-associated colorectal cancer (IBD-CRC) accounts for only 1-2% of all cases of colorectal cancer, IBD with colon involvement is among the top three high-risk conditions for colorectal cancer. Today, colorectal cancer accounts for approximately 10-15% of all deaths among IBD patients. Indeed, patients with IBD colitis are six times more likely to develop colorectal cancer than the general population and have a higher frequency of multiple synchronous colorectal cancers. Since IBD-CRC was first described in 1925, the colon remains the primary site of neoplasms in IBD patients today. Ulcerative colitis-associated colorectal cancer is most common in the rectum and sigmoid colon, whereas Crohn's disease-associated colorectal cancer is evenly distributed between the different colon segments. Chemoprevention of colorectal cancer remains an important goal, and colonoscopy surveillance programs are critical to early detection in these patients. Newer methods, such as chromoendoscopy, are currently being investigated as complementary techniques to enhance early detection of dysplasia and cancer in this high-risk population. We present a comprehensive review of the relationship between inflammatory bowel disease and colorectal cancer. Major themes covered include risk factors for IBD-CRC and the molecular pathobiology of progression from dysplasia to cancer, endoscopic surveillance and new methods for early detection of dysplasia, approaches to prevention of IBD-CRC, and current recommendations and controversies regarding the treatment of dysplasia. In particular, disagreement has arisen over optimal management of low-grade dysplasia, with some IBD experts now advocating close colonoscopic surveillance of patients with low-grade dysplasia rather then total colectomy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Comparison of molecular alterations in sporadic colon cancer and colitis-associated colon cancer. (Adapted from Itzkowitz and Harpaz 2004.)
Figure 2.
Figure 2.
A 28-year-old male with history of ulcerative pancolitis and primary sclerosing cholangitis diagnosed in 1997 who had no dysplasia on surveillance colonoscopy 2 years prior to this surveillance colonoscopy. This ulceration in the ascending colon revealed adenocarcinoma. This patient subsequently underwent total colectomy with ileostomy.

References

    1. Calkins BM, Lilienfeld AM, Garland CF, et al. : Trends in incidence rates of ulcerative colitis and Crohn's disease. Dig Dis Sci 29(10):913–920, 1984 - PubMed
    1. Loftus EV, Jr: Management of extraintestinal manifestations and other complications of inflammatory bowel disease. Curr Gastroenterol Rep 6(6):506–513, 2004 - PubMed
    1. Crohn BB: The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Amer J Med Sci 170:220–228, 1925
    1. Munkholm P: Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18(suppl 2):1–5, 2003 - PubMed
    1. Lennard-Jones JE, Ritchie JK, Williams CB: Cancer surveillance in ulcerative colitis: experience over 15 years. Lancet 2:149–152, 1983 - PubMed

LinkOut - more resources